Moderna working on booster shot to increase protection against South African coronavirus variant

Moderna's coronavirus vaccine is still doing its job. But when it comes to the COVID-19 variant first found in South Africa, there could be some room for improvement.
More transmissible variants of COVID-19 first appeared overseas in the past month, and have since been found in the U.S. Both the Pfizer and Moderna vaccines have been found effective against the B.1.1.7 variant that was first found in London, and Moderna has confirmed it found no reduction in antibodies when its vaccine was used against that strain. But when researching the B1.351 strain, Moderna saw a sixfold reduction in antibodies produced, a study released Monday indicates.
Despite the shortfall, Moderna affirmed that the antibodies produced with the vaccine "remain above levels that are expected to be protective" against either strain. But "as an insurance policy," the company is working on a booster shot that could make the vaccine more effective against the South Africa-based strain, Moderna's chief medical officer Dr. Tal Zaks told The New York Times. "I don't know if we need it, and I hope we don't," he added.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
So far, there has been no evidence to suggest the B1.351 strain is more deadly than the more widespread virus, only that it spreads faster. The B.1.1.7 variant also spreads up to 50 percent faster than the original strain, and the U.K. has found early evidence that it could be more deadly.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kathryn is a graduate of Syracuse University, with degrees in magazine journalism and information technology, along with hours to earn another degree after working at SU's independent paper The Daily Orange. She's currently recovering from a horse addiction while living in New York City, and likes to share her extremely dry sense of humor on Twitter.
-
US foodies brace for tariff war
Under The Radar Shoppers stocking up on imported olive oil, maple syrup and European wine as price hikes loom
By Chas Newkey-Burden, The Week UK Published
-
How Canadian tariffs could impact tourism to the US
In the Spotlight Canadians represent the largest group of foreign visitors to the United States. But they may soon stop visiting.
By Justin Klawans, The Week US Published
-
Entitlements: DOGE goes after Social Security
Feature Elon Musk is pushing false claims about Social Security fraud
By The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published